JME Group, Inc. is a privately held, biotechnology company founded on March 2014 in New Jersey, U.S.

 

 

The company embarked on a project to develop and commercialize a safer and affordable enzyme replacement therapy (ERT) for metabolic and lysosomal storage diseases (a group of rare (orphan) diseases deficient in lysosomal enzymes) via oral administration (hence Oral-ERT) using plant-derived recombinant human enzymes or proteins plus natural non-GMO plant products for improvement of human and animal health. The first enzyme in the pipeline using this platform is a recombinant human lysosomal acid alpha-glucosidase (GAA) or acid maltase produced in tobacco seeds for the treatment of acid maltase deficiency (AMD or POMPE disease). 

​

Our plan is to clinically develop and commercialize some of these products to initially address the unmet needs of the estimated ~4000 to 5,000 adult and juvenile POMPE patients in the USA and later for the ~120,000 later-onset patients worldwide.  However, these estimates will increase by one-third if the fatal infantile cases survive.

​

We will apply to trademark our oral enzyme replacement therapy as “ Oral-ERT™ & TABZYME ™, POMPEZYME™ "

 

Added to our innovative products is our Dietary supplement "BARZYME ™ which has promising energy , muscle weakness , and weight maintenance applications. Barzyme will be in production and available through out site first quarter of 2022